Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT02312882
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    Tofacitinib 5 mg tablet taken by mouth twice a day.

Study Details

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Key Dates

Start date
Dec 31, 2014
Status verified
Oct 2017
Primary completion
Aug 31, 2015
Completion
Aug 31, 2015

Study Design

Enrollment
40 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tofacitinib
    Participants will receive tofacitinib for 3 months.

Primary Outcome Measure

Percent Change in Severity of Alopecia Tool (SALT) Score [ Time Frame: 0 and 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityStanfordCalifornia94305-

Find similar trials in Stanford, CA

By research site
Stanford University· Stanford, CA

Related Studies